Skip to main content
Pharmena S.A. logo

Pharmena S.A. — Investor Relations & Filings

Ticker · PHR ISIN · PLPHRMN00011 LEI · 259400RHT936BBKW0955 WAR Manufacturing
Open in API
Filings indexed 649 across all filing types
Latest filing 2024-02-29 Regulatory Filings
Country PL Poland
Listing WAR PHR

About Pharmena S.A.

https://www.pharmena.eu/

Pharmena S.A. is a specialty healthcare company focused on the development and commercialization of innovative products based on its patented active ingredient, 1-MNA. This molecule is a naturally occurring metabolite of niacin (vitamin B3) that plays a crucial role in cellular metabolism. The company's technology leverages the ability of 1-MNA to optimize the levels of the coenzyme NAD+, which decline with age and are vital for cellular function and regeneration. The product portfolio includes specialized cosmeceuticals, such as the Dermena line for hair loss, and dietary supplements designed to address the effects of cellular aging.

Recent filings

Filing Released Lang Actions
Oświadczenie zarządu skonsolidowane sprawozdanie za 2023
Regulatory Filings Classification · 95% confidence The document is a formal statement (Oświadczenie) signed by the Management Board of Pharmena S.A. certifying the accuracy and compliance of the consolidated financial statements and the management report for the year 2023. It does not contain the actual financial statements or substantive financial data itself, but rather serves as an officer certification/attestation. According to the 'Certification Rule', documents that are primarily officer certifications or attestations should be classified as Regulatory Filings (RNS). FY 2023
2024-02-29 Polish
Sprawozdanie Audytora z badania skonsolidowanego sprawozdania finansowego za 2023 - podpis
Audit Report / Information Classification · 98% confidence The document text provided consists entirely of XML signature blocks (XML Digital Signature structure, including SignedInfo, SignatureValue, KeyInfo, and Object containing SignedProperties). This structure is typical for digitally signed documents, often used to verify the authenticity and integrity of an official filing or report. The reference URI within the signature block points to a file named "KPW_Audyt_sprawozdanie_z_badania_JZP_SSF_MSSF_z_701_GK_Pharmena_SA.xhtml". The Polish terms 'Audyt sprawozdanie z badania' translate to 'Audit report on the examination'. Since the content is the signature block itself, and the referenced document is an audit report, this document is most likely the Audit Report or the container/wrapper for it. Given the explicit mention of 'Audyt sprawozdanie z badania' (Audit report), the most appropriate classification is Audit Report / Information (AR). The document length is short (4430 chars), but it is not an announcement *about* a report; it *is* the verifiable signature structure of the report itself. FY 2023
2024-02-29 Polish
Sprawozdanie Audytora z badania skonsolidowanego sprawozdania finansowego za 2023
Audit Report / Information Classification · 99% confidence The document text is titled "SPRAWOZDANIE NIEZALEŻNEGO BIEGŁEGO REWIDENTA Z BADANIA ROCZNEGO SKONSOLIDOWANEGO SPRAWOZDANIA FINANSOWEGO" (Independent Auditor's Report on the Audit of the Annual Consolidated Financial Statements) for the period ending December 31, 2023. It explicitly discusses the audit process, the auditor's opinion, compliance with accounting standards (MSSF/IFRS), and key audit matters. This content directly corresponds to the definition of an Audit Report/Information, which is categorized as 'AR'. Although it relates to the annual period, it is the auditor's opinion/report, not the full Annual Report (10-K) itself, nor is it a mere announcement of a report (RPA/RNS), given its substantial length and detailed content. FY 2023
2024-02-29 Polish
Sprawozdanie z działalności Grupy Kapitałowej Pharmena za 2023- podpis
Audit Report / Information Classification · 95% confidence The document text consists entirely of XML Digital Signature blocks (DSig) containing elements like Signature, SignedInfo, Reference, DigestValue, and KeyInfo with X509Certificate data. Crucially, the references point to a file named "Grupa_Kapitalowa_Pharmena_Sprawozdanie_z_dzialalnosci_2023.xhtml". The presence of 'Sprawozdanie z działalności' (Activity Report in Polish) strongly suggests this is a formal report. Since the document itself is just the signature block and not the content of the report, and given the context of annual reporting implied by '2023', this is likely related to the Annual Report (10-K equivalent for Polish context, but we must map to provided codes). However, the document provided is purely the digital signature metadata, which often accompanies regulatory filings or official reports. Since the referenced file name implies a comprehensive annual report ('Sprawozdanie z działalności 2023'), the underlying document is likely an Annual Report (10-K). If this were an announcement *about* the report, it would be RPA or RNS. Since the text provided is the signature block *of* the report file (as indicated by the URI reference), it represents the report itself, which is best classified as the Annual Report (10-K) based on the content implied by the filename, even though the text is technical metadata. FY 2023
2024-02-29 Polish
Sprawozdanie z działalności Grupy Kapitałowej Pharmena za 2023
Management Reports Classification · 99% confidence The document title is "Grupa Kapitałowa Pharmena S.A. Sprawozdanie Zarządu za 2023 rok" which translates to "Pharmena Capital Group S.A. Management Report for the year 2023". The table of contents details extensive sections covering selected financial data, principles of consolidated financial statement preparation, management's description of strategy, risk factors, and detailed financial disclosures for the entire year 2023. This structure and content strongly indicate a comprehensive annual report, which corresponds to the definition of a 10-K filing, even though the document appears to be in Polish (Sprawozdanie Zarządu za rok obrotowy is the Polish equivalent of the Management Discussion and Analysis section typically found in a 10-K or Annual Report). Given the comprehensive nature covering the full fiscal year and detailed financial/operational review, the most appropriate classification is Annual Report (10-K).
2024-02-29 Polish
Skonsolidowane sprawozdanie finansowe za 2023- podpis
Regulatory Filings Classification · 95% confidence The document text consists entirely of XML digital signature blocks (SignedInfo, SignatureValue, KeyInfo, QualifyingProperties) used to verify the integrity and authenticity of an attached file. The reference URI within the signature block points to "phr-2023-12-31-pl.zip". This structure strongly indicates that the document itself is not the primary financial report but rather a container or wrapper file (likely an XML wrapper for an XBRL filing or similar submission) whose main purpose is to digitally sign the actual data package (the zip file). Since the content is purely metadata about a signature and references a file dated '2023-12-31', it is a regulatory submission artifact. Given the context of corporate filings, a document that is essentially a signature wrapper for a data package, and does not contain the actual financial narrative or results, is best classified as a general Regulatory Filing (RNS) or potentially a Financial Supplement Data (XLSX) if the zip contained structured data, but RNS is the safer fallback for signature blocks themselves, unless the content clearly points to a specific report type. However, the presence of the zip file reference containing data for '2023-12-31' suggests it is the submission wrapper for a periodic report. Since the document is not the report itself (per Rule 2), and it is a formal submission artifact, RNS is the most appropriate general classification for this type of metadata wrapper.
2024-02-29 Polish

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.